S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)

Markus Cornberg; Lisa Sandmann; Ulrike Protzer; Claus Niederau; Frank Tacke; Thomas Berg; Dieter Glebe; Wolfgang Jilg; Heiner Wedemeyer; Stefan Wirth; Christoph Höner zu Siederdissen; Petra Lynen-Jansen; Pia van Leeuwen; Jörg Petersen; Collaborators:

doi:10.1055/a-1498-2512

Zeitschrift für Gastroenterologie, Table of Contents

Z Gastroenterol 2021; 59(07): 691-776
DOI: 10.1055/a-1498-2512

Leitlinie

S3-Leitlinie der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) zur Prophylaxe, Diagnostik und Therapie der Hepatitis-B-Virusinfektion – (AWMF-Register-Nr. 021-11)

Markus Cornberg

¹Deutsches Zentrum für Infektionsforschung (DZIF), Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover; Centre for individualised infection Medicine (CiiM), Hannover

²Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover

,

Lisa Sandmann

²Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover

,

Ulrike Protzer

³Institut für Virologie, Technische Universität München/Helmholtz Zentrum München, München

,

Claus Niederau

⁴Oberhausen

,

Frank Tacke

⁵Medizinische Klinik m. S. Hepatologie und Gastroenterologie, Charité Universitätsmedizin Berlin, Berlin

,

Thomas Berg

⁶Klinik und Poliklinik für Gastroenterologie und Rheumatologie, Universitätsklinikum Leipzig, Leipzig

,

Dieter Glebe

⁷Institut für Medizinische Virologie, Nationales Referenzzentrum für Hepatitis-B-Viren und Hepatitis-D-Viren, Justus-Liebig-Universität Gießen, Gießen

,

Wolfgang Jilg

⁸Institut für Medizinische Mikrobiologie und Hygiene, Universität Regensberg, Regensburg

,

Heiner Wedemeyer

²Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover

,

Stefan Wirth

⁹Zentrum für Kinder- und Jugendmedizin, Helios Universitätsklinikum Wuppertal, Wuppertal

,

Christoph Höner zu Siederdissen

²Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover

,

Petra Lynen-Jansen

¹⁰Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Berlin

,

Pia van Leeuwen

¹⁰Deutsche Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS), Berlin

,

Jörg Petersen

¹¹IFI Institut für Interdisziplinäre Medizin an der Asklepios Klinik St. Georg, Hamburg

,

Collaborators:

› Author Affiliations

Abstract

Full Text

References

Literatur
1 World Health Organization. Hepatitis B. 2019 Im Internet: https://www.who.int/news-room/fact-sheets/detail/hepatitis-b
2 Robert Koch-Institut. Infektionsepidemiologisches Jahrbuch meldepflichtiger Krankheiten für 2018. 2019 Im Internet: https://www.rki.de/DE/Content/Infekt/Jahrbuch/Jahrbuch_2018.pdf?__blob=publicationFile
3 Stahmeyer JT, Becker H, Heidelberger S. et al Kosten einer leitliniengerechten Versorgung von Hepatitis-B-Patienten in Deutschland. Z Gastroenterol 2012; 50: 745-752
4 Cornberg M, Protzer U, Dollinger MM. et al Prophylaxe, diagnostik und therapie der hepatitis-B-virus-(HBV-)infektion: „Upgrade“ der leitlinie, AWMF-register-Nr.: 021/011. Z Gastroenterol 2007; 45: 525-574
5 Cornberg M, Protzer U, Petersen J. et al Prophylaxis, diagnosis and therapy of hepatitis B virus infection the German guideline. Z Gastroenterol 2011; 49: 871-930
6 European Association for the Study of the Liver (EASL). EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol 2017; 67: 370-398
7 Terrault NA, Bzowej NH, Chang KM. et al AASLD Guidelines for Treatment of Chronic Hepatitis B. Hepatology 2016; 63: 261-283
8 Terrault NA, Lok ASF, McMahon BJ. et al Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology 2018; 67: 1560-1599
9 Greten TF, Malek NP, Schmidt S. et al Diagnostik und Therapie des hepatozellulären Karzinoms. Z Gastroenterol 2013; 51: 1269-1326
10 Castera L, Yuen Chan HL, Arrese M. et al EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol 2015; 63: 237-264
11 Sarrazin C, Zimmermann T, Berg T. et al Prophylaxis, diagnosis and therapy of hepatitis-C-virus (HCV) infection: the German guidelines on the management of HCV infection. Z Gastroenterol 2018; 56: 756
12 Sarrazin C, Zimmermann T, Berg T. et al Prophylaxe, Diagnostik und Therapie der Hepatitis-C-Virus(HCV)- Infektion. Z Gastroenterol 2020; 58: 1110-1131
13 Lynen Jansen P, Preiß JC, Muche-Borowski C. et al Das Leitlinienprogramm der DGVS. Z Gastroenterol 2013; 51: 643-650
14 Muche-Borowski C, Selbmann H, Nothacker M. et al Das AWMF-Regelwerk Leitlinien. 2013
15 Blümle A, Sow D, Nothacker M. et al Manual Systematische Recherche für Evidenzsynthesen und Leitlinien. Cochrane Deutschl Stift Inst für Evidenz der Medizin, Inst für Medizinische Biometrie und Stat Freiburg, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – Inst für Medizinisches Wissensmanagement, Är 2019. 2. Auflage. 1-63
16 Scheiblauer H, Soboll H, Nick S. Evaluation of 17 CE-marked HBsAg assays with respect to clinical sensitivity, analytical sensitivity, and hepatitis B virus mutant detection. J Med Virol 2006; 78: S66-S70
17 Westhoff TH, Jochimsen F, Schmittel A. et al Fatal hepatitis B virus reactivation by an escape mutant following rituximab therapy. Blood 2003; 102: 1930
18 Awerkiew S, Däumer M, Reiser M. et al Reactivation of an occult hepatitis B virus escape mutant in an anti-HBs positive, anti-HBc negative lymphoma patient. J Clin Virol 2007; 38: 83-86
19 Brown RS, McMahon BJ, Lok ASF. et al Antiviral therapy in chronic hepatitis B viral infection during pregnancy: A systematic review and meta-analysis. Hepatology 2016; 63: 319-333
20 Li W, Jia L, Zhao X. et al Efficacy and safety of tenofovir in preventing mother-to-infant transmission of hepatitis B virus: A meta-analysis based on 6 studies from China and 3 studies from other countries. BMC Gastroenterol 2018; 18: 121
21 Hyun MH, Lee YS, Kim JH. et al Systematic review with meta-analysis: the efficacy and safety of tenofovir to prevent mother-to-child transmission of hepatitis B virus. Aliment Pharmacol Ther 2017; 45: 1493-1505
22 Pan CQ, Duan Z, Dai E. et al Tenofovir to prevent hepatitis B transmission in mothers with high viral load. N Engl J Med 2016; 374: 2324-2334
23 World Health Organization. Prevention of mother-to-child transmission of hepatitis B virus: Guidelines on antiviral prophylaxis in pregnancy. Geneva World Heal Organ; 2020 Licence: CC BY-NC-SA 3.0 IGO. Im Internet: https://apps.who.int/iris/bitstream/handle/10665/333391/9789240002708-eng.pdf?sequence=1&isAllowed=y
24 Jourdain G, Ngo-Giang-Huong N, Harrison L. et al Tenofovir versus Placebo to Prevent Perinatal Transmission of Hepatitis B. N Engl J Med 2018; 378: 911-923
25 Lin Y, Liu Y, Ding G. et al Efficacy of tenofovir in preventing perinatal transmission of HBV infection in pregnant women with high viral loads. Sci Rep 8, 15514 (2018)
26 Walz A, Wirth S, Hucke J. et al Vertical Transmission of Hepatitis B Virus (HBV) from Mothers Negative for HBV Surface Antigen and Positive for Antibody to HBV Core Antigen. J Infect Dis 2009; 200: 1227-1231
27 Robert Koch-Insitut. Zur Situation bei wichtigen Infektionskrankheiten in Deutschland: Virushepatitis B, C und D im Jahr 2009. Epidemiol Bull 2009; 20: 177-190
28 Ganem D, Prince AM. Hepatitis B Virus Infection – Natural History and Clinical Consequences. N Engl J Med 2004; 350: 1118-1129
29 McMahon BJ. Natural history of chronic hepatitis B. Clin Liver Dis 2010; 14: 381-396
30 Veldhuijzen IK, Toy M, Hahné SJM. et al Screening and Early Treatment of Migrants for Chronic Hepatitis B Virus Infection Is Cost-Effective. Gastroenterology 2010; 138: 522-530
31 Colloredo Mels G, Bellati G, Leandro G. et al Role of IgM antibody to hepatitis B core antigen in the diagnosis of hepatitis B exacerbations. Arch Virol Suppl 1993; 8: 203-211
32 Chen CJ, Yang HI, Su J. et al Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA Level. J Am Med Assoc 2006; 295: 65-73
33 Iloeje UH, Yang HI, Su J. et al Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006; 130: 678-686
34 Chen G, Lin W, Shen F. et al Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am J Gastroenterol 2006; 101: 1797-1803
35 Yang HI, Lu SN, Liaw YF. et al Hepatitis B e Antigen and the Risk of Hepatocellular Carcinoma. N Engl J Med 2002; 347: 168-174
36 Cornberg M, Wong VWS, Locarnini S. et al The role of quantitative hepatitis B surface antigen revisited. J Hepatol 2017; 66: 398-411
37 Tseng TC, Liu CJ, Yang HC. et al Serum hepatitis B surface antigen levels help predict disease progression in patients with low hepatitis B virus loads. Hepatology 2013; 57: 441-450
38 Wedemeyer H, Manns MP. Epidemiology, pathogenesis and management of hepatitis D: Update and challenges ahead. Nat Rev Gastroenterol Hepatol 2010; 7: 31-40
39 Bremer B, Anastasiou OE, Ciesek S. et al Automated nucleic acid isolation methods for HDV viral load quantification can lead to viral load underestimation. Antivir Ther 2019; 24: 117-123
40 Heese F, Görg C. Diagnostische wertigkeit einer internistischen referenzsonografie (DEGUM-Stufe 3). Ultraschall der Medizin 2006; 27: 220-224
41 Sheu JC, Sung JL, Chen DS. et al Growth rate of asymptomatic hepatocellular carcinoma and its clinical implications. Gastroenterology 1985; 89: 259-266
42 Barbara L, Benzi G, Gaiani S. et al Natural history of small untreated hepatocellular carcinoma in cirrhosis: A multivariate analysis of prognostic factors of tumor growth rate and patient survival. Hepatology 1992; 16: 132-137
43 Trinchet JC, Chaffaut C, Bourcier V. et al Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: A randomized trial comparing 3- and 6-month periodicities. Hepatology 2011; 54: 1987-1997
44 Wang JH, Chang KC, Kee KM. et al Hepatocellular carcinoma surveillance at 4-vs. 12-month intervals for patients with chronic viral hepatitis: A randomized study in community. Am J Gastroenterol 2013; 108: 416-424
45 Sarri G, Westby M, Bermingham S. et al Diagnosis and management of chronic hepatitis B in children, young people, and adults: summary of NICE guidance. BMJ 2013; 346: f3893
46 Singal A, Volk ML, Waljee A. et al Meta-analysis: Surveillance with ultrasound for early-stage hepatocellular carcinoma in patients with cirrhosis. Aliment Pharmacol Ther 2009; 30: 37-47
47 Sarin SK, Kumar M, Lau GK. et al Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update. Hepatol Int 2016; 10: 1-98
48 Korean Association for the Study of the Liver. KASL clinical practice guidelines: management of chronic hepatitis B. Clin Mol Hepatol 2016; 22: 18-75
49 Park JW, Lee JH, Suh KS. et al 2014 Korean Liver Cancer Study Group-National Cancer Center Korea practice guideline for the management of hepatocellular carcinoma. Korean J Radiol 2015; 16: 465-522
50 Thiele M, Gluud LL, Fialla AD. et al Large variations in risk of hepatocellular carcinoma and mortality in treatment Naïve hepatitis B patients: Systematic review with Metaanalyses. PLoS One 2014; 9: e107177
51 Galle PR, Forner A, Llovet JM. et al EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. J Hepatol 2018; 69: 182-236
52 Trevisani F, D’Intino PE, Morselli-Labate AM. et al Serum α-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: Influence of HBsAg and anti-HCV status. J Hepatol 2001; 34: 570-575
53 Papatheodoridis G, Dalekos G, Sypsa V. et al PAGE-B predicts the risk of developing hepatocellular carcinoma in Caucasians with chronic hepatitis B on 5-year antiviral therapy. J Hepatol 2016; 64: 800-806
54 Wong GLH, Wong VWS, Choi PCL. et al Development of a non-invasive algorithm with transient elastography (Fibroscan) and serum test formula for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2010; 31: 1095-1103
55 Wong GLH, Chan HLY, Choi PCL. et al Non-invasive algorithm of enhanced liver fibrosis and liver stiffness measurement with transient elastography for advanced liver fibrosis in chronic hepatitis B. Aliment Pharmacol Ther 2014; 39: 197-208
56 Wong GLH, Wong VWS, Choi PCL. et al Increased liver stiffness measurement by transient elastography in severe acute exacerbation of chronic hepatitis B. J Gastroenterol Hepatol 2009; 24: 1002-1007
57 Papatheodoridis GV, Manolakopoulos S, Liaw YF. et al Follow-up and indications for liver biopsy in HBeAg-negative chronic hepatitis B virus infection with persistently normal ALT: A systematic review. J Hepatol 2012; 57: 196-202
58 Kumar M, Satapathy S, Monga R. et al A randomized controlled trial of lamivudine to treat acute hepatitis B. Hepatology 2007; 45: 97-101
59 Yu JW, Sun LJ, Zhao YH. et al The study of efficacy of lamivudine in patients with severe acute hepatitis B. Dig Dis Sci 2010; 55: 775-783
60 Wiegand J, Wedemeyer H, Franke A. et al Treatment of severe, nonfulminant acute hepatitis B with lamivudine vs placebo: A prospective randomized double-blinded multicentre trial. J Viral Hepat 2014; 21: 744-750
61 Mantzoukis K, Rodríguez-Perálvarez M, Buzzetti E. et al Pharmacological interventions for acute hepatitis B infection: An attempted network meta-analysis. Cochrane Database Syst Rev 2017; 3: CD011645
62 Tillmann HL, Hadem J, Leifeld L. et al Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience. J Viral Hepat 2006; 13: 256-263
63 Jochum C, Maischack F, Anastasiou OE. et al Therapie der akuten fulminanten Hepatitis B mit Nucleos(t)id-Analogen ist sicher und führt nicht zur Chronifizierung der Hepatitis B. Z Gastroenterol 2016; 54: 1306-1311
64 Yu JW, Sun LJ, Yan BZ. et al Lamivudine treatment is associated with improved survival in fulminant hepatitis B. Liver Int 2011; 31: 499-506
65 Brunetto MR, Oliveri F, Coco B. et al Outcome of anti-HBe positive chronic hepatitis B in alpha-interferon treated and untreated patients: A long term cohort study. J Hepatol 2002; 36: 263-270
66 Kumar M, Sarin SK, Hissar S. et al Virologic and Histologic Features of Chronic Hepatitis B Virus-Infected Asymptomatic Patients With Persistently Normal ALT. Gastroenterology 2008; 134: 1376-1384
67 Lai M, Hyatt BJ, Nasser I. et al The clinical significance of persistently normal ALT in chronic hepatitis B infection. J Hepatol 2007; 47: 760-767
68 Tsang PSY, Trinh H, Garcia RT. et al Significant Prevalence of Histologic Disease in Patients With Chronic Hepatitis B and Mildly Elevated Serum Alanine Aminotransferase Levels. Clin Gastroenterol Hepatol 2008; 6: 569-574
69 Papatheodoridis GV, Manesis EK, Manolakopoulos S. et al Is there a meaningful serum Hepatitis B virus DNA cutoff level for therapeutic decisions in hepatitis B e antigen-negative chronic hepatitis B virus infection?. Hepatology 2008; 48: 1451-1459
70 Wu IC, Lai CL, Bui Han SH. et al Efficacy of entecavir in chronic hepatitis b patients with mildly elevated alanine aminotransferase and biopsy-proven histological damage. Hepatology 2010; 51: 1185-1189
71 Chen JD, Yang HI, Iloeje UH. et al Carriers of Inactive Hepatitis B Virus Are Still at Risk for Hepatocellular Carcinoma and Liver-Related Death. Gastroenterology 2010; 138: 1747-1754
72 Kim JH, Sinn DH, Kang W. et al Low-level viremia and the increased risk of hepatocellular carcinoma in patients receiving entecavir treatment. Hepatology 2017; 66: 335-343
73 Sinn DH, Lee J, Goo J. et al Hepatocellular carcinoma risk in chronic hepatitis B virus-infected compensated cirrhosis patients with low viral load. Hepatology 2015; 62: 694-701
74 Zoutendijk R, Reijnders JG, Zoulim F. et al Virological response to entecavir is associated with a better clinical outcome in chronic hepatitis B patients with cirrhosis. Gut 2013; 62: 760-765
75 Singal AK, Salameh H, Kuo YF. et al Meta-analysis: The impact of oral anti-viral agents on the incidence of hepatocellular carcinoma in chronic hepatitis B. Aliment Pharmacol Ther 2013; 38: 98-106
76 Lok ASF, McMahon BJ, Brown RS. et al Antiviral therapy for chronic hepatitis B viral infection in adults: A systematic review and meta-analysis. Hepatology 2016; 63: 284-306
77 Huang G, Li P, Lau WY. et al Antiviral therapy reduces hepatocellular carcinoma recurrence in patients with low HBV-DNA levels: A randomized controlled trial. Ann Surg 2018; 268: 943-954
78 Chen VL, Yeh ML, Le AK. et al Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. Aliment Pharmacol Ther 2018; 48: 44-54
79 He L, Liu X, Zhao Y. et al Efficacy of Nucleot(s)ide Analogs Therapy in Patients with Unresectable HBV-Related Hepatocellular Carcinoma: A Systematic Review and Meta-Analysis. Dis Markers 2017; 2017: 7075935
80 Yuan P, Chen P, Qian Y. Evaluation of antiviral therapy performed after curative therapy in patients with HBV-related hepatocellular carcinoma: An updated meta-analysis. Can J Gastroenterol Hepatol 2016; 2016: 5234969
81 Xia BW, Zhang YC, Wang J. et al Efficacy of antiviral therapy with nucleotide/nucleoside analogs after curative treatment for patients with hepatitis B virus-related hepatocellular carcinoma: A systematic review and meta-analysis. Clin Res Hepatol Gastroenterol 2015; 39: 458-468
82 Huang G, Lau WY, Wang ZG. et al Antiviral therapy improves postoperative survival in patients with hepatocellular carcinoma. Ann Surg 2015; 261: 56-66
83 Zhou Y, Zhang Z, Zhao Y. et al Antiviral therapy decreases recurrence of hepatitis b virus-related hepatocellular carcinoma after curative resection: A meta-analysis. World J Surg 2014; 38: 2395-2402
84 Yin J, Li N, Han Y. et al Effect of antiviral treatment with nucleotide/nucleoside analogs on postoperative prognosis of hepatitis B virus-related hepatocellular carcinoma: A two-stage longitudinal clinical study. J Clin Oncol 2013; 31: 3647-3655
85 Wong JSW, Wong GLH, Tsoi KKF. et al Meta-analysis: The efficacy of anti-viral therapy in prevention of recurrence after curative treatment of chronic hepatitis B-related hepatocellular carcinoma. Aliment Pharmacol Ther 2011; 33: 1104-1112
86 Reddy KR, Beavers KL, Hammond SP. et al American Gastroenterological Association Institute guideline on the prevention and treatment of hepatitis B virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 215-219
87 Sarmati L, Andreoni M, Antonelli G. et al Recommendations for screening, monitoring, prevention, prophylaxis and therapy of hepatitis B virus reactivation in patients with haematologic malignancies and patients who underwent haematologic stem cell transplantation – a position paper. Clin Microbiol Infect 2017; 23: 935-940
88 Chen JZJQ, Liao ZW, Huang FL. et al Efficacy and safety of tenofovir disoproxil fumarate in preventing vertical transmission of hepatitis B in pregnancies with high viral load. Sci Rep 2017; 7: 4132
89 Glebe D, van Bömmel F, Dudareva S. et al Prävention der nosokomialen Übertragung von Hepatitis-B-Virus (HBV) und Hepatitis-C-Virus (HCV) durch im Gesundheitswesen Tätige: Empfehlungen der Deutschen Vereinigung zur Bekämpfung der Viruskrankheiten (DVV) e. V. Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz 2020; 63: 218-225
90 Mazzaro C, Dal Maso L, Urraro T. et al Hepatitis B virus related cryoglobulinemic vasculitis: A multicentre open label study from the Gruppo Italiano di Studio delle Crioglobulinemie – GISC. Dig Liver Dis 2016; 48: 780-784
91 Wang WN, Wu MY, Ma FZ. et al Meta-analysis of the efficacy and safety of nucleotide/nucleoside analog monotherapy for hepatitis B virus-associated glomerulonephritis. Clin Nephrol 2016; 85: 21-29
92 Yang Y, Ma YP, Chen DP. et al A meta-Analysis of antiviral therapy for hepatitis b virus-Associated membranous nephropathy. PLoS One 2016; 11: e0160437
93 Hui CK, Leung N, Yuen ST. et al Natural history and disease progression in Chinese chronic hepatitis B patients in immune-tolerant phase. Hepatology 2007; 46: 395-401
94 Andreani T, Serfaty L, Mohand D. et al Chronic Hepatitis B Virus Carriers in the Immunotolerant Phase of Infection: Histologic Findings and Outcome. Clin Gastroenterol Hepatol 2007; 5: 636-641
95 Chu CM, Hung SJ, Lin J. et al Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med 2004; 116: 829-834
96 You SL, Yang HI, Chen CJ. Seropositivity of hepatitis B e antigen and hepatocellular carcinoma. Ann Med 2004; 36: 215-224
97 Manno M, Cammà C, Schepis F. et al Natural history of chronic HBV carriers in Northern Italy: Morbidity and mortality after 30 years. Gastroenterology 2004; 127: 756-763
98 Tseng TC, Liu CJ, Yang HC. et al High levels of hepatitis B surface antigen increase risk of hepatocellular carcinoma in patients with low HBV load. Gastroenterology 2012; 142: 1140-1149.e3
99 Tseng TC, Liu CJ, Chen CL. et al Risk stratification of hepatocellular carcinoma in hepatitis B virus e antigen-negative carriers by combining viral biomarkers. J Infect Dis 2013; 208: 584-593
100 Cornberg M, Suk-Fong Lok A, Terrault NA. et al Guidance for design and endpoints of clinical trials in chronic hepatitis B – Report from the 2019 EASL-AASLD HBV Treatment Endpoints Conference‡. J Hepatol 2020; 72: 539-557
101 Kim GA, Lim YS, An J. et al HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis b: Clinical outcomes and durability. Gut 2014; 63: 1325-1332
102 Yuen MF, Wong DKH, Fung J. et al HBsAg Seroclearance in Chronic Hepatitis B in Asian Patients: Replicative Level and Risk of Hepatocellular Carcinoma. Gastroenterology 2008; 135: 1192-1199
103 Yip TCF, Wong GLH, Chan HLY. et al HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues. J Hepatol 2019; 70: 361-370
104 Wong GLH, Chan HLY, Mak CWH. et al Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients With liver cirrhosis. Hepatology 2013; 58: 1537-1547
105 Arends P, Sonneveld MJ, Zoutendijk R. et al Entecavir treatment does not eliminate the risk of hepatocellular carcinoma in chronic hepatitis B: Limited role for risk scores in Caucasians. Gut 2015; 64: 1289-1295
106 Papatheodoridis GV, Lampertico P, Manolakopoulos S. et al Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: A systematic review. J Hepatol 2010; 53: 348-356
107 Kim SS, Hwang JC, Lim SG. et al Effect of virological response to entecavir on the development of hepatocellular carcinoma in hepatitis B viral cirrhotic patients: Comparison between compensated and decompensated cirrhosis. Am J Gastroenterol 2014; 109: 1223-1233
108 Marcellin P, Gane E, Buti M. et al Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: A 5-year open-label follow-up study. Lancet 2013; 381: 468-475
109 Chang TT, Liaw YF, Wu SS. et al Long-term entecavir therapy results in the reversal of fibrosis/cirrhosis and continued histological improvement in patients with chronic hepatitis B. Hepatology 2010; 52: 886-893
110 Niederau C, Heintges T, Lange S. et al Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334: 1422-1427
111 Lin SM, Yu ML, Lee CM. et al Interferon therapy in HBeAg positive chronic hepatitis reduces progression to cirrhosis and hepatocellular carcinoma. J Hepatol 2007; 46: 45-52
112 Yuen MF, Hui CK, Cheng CC. et al Long-term follow-up of interferon alfa treatment in Chinese patients with chronic hepatitis B infection: The effect on hepatitis B e antigen seroconversion and the development of cirrhosis-related complications. Hepatology 2001; 34: 139-145
113 Jacobson IM, Washington MK, Buti M. et al Factors Associated With Persistent Increase in Level of Alanine Aminotransferase in Patients With Chronic Hepatitis B Receiving Oral Antiviral Therapy. Clin Gastroenterol Hepatol 2017; 15: 1087-1094.e2
114 Liang KH, Hsu CW, Chang ML. et al Peginterferon Is Superior to Nucleos(t)ide Analogues for Prevention of Hepatocellular Carcinoma in Chronic Hepatitis B. J Infect Dis 2016; 213: 966-974
115 Lau GKK, Piratvisuth T, Kang XL. et al Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352: 2682-2695
116 Marcellin P, Lau GKK, Bonino F. et al Peginterferon Alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351: 1206-1217
117 Sonneveld MJ, Zoutendijk R, Hansen BE. et al Pegylated interferon results in higher serological, but not virological, response rates when compared to continuous entecavir. Antivir Ther 2012; 17: 1605-1608
118 Van Nunen AB, Hansen BE, Suh DJ. et al Durability of HBeAG seroconversion following antiviral therapy for chronic hepatitis B: Relation to type of therapy and pretreatment serum hepatitis B virus DNA and alanine aminotransferase. Gut 2003; 52: 420-424
119 Papatheodoridis GV, Chan HLY, Hansen BE. et al Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy. J Hepatol 2015; 62: 956-967
120 Dave S, Park S, Murad MH. et al Comparative Effectiveness of Entecavir vs Tenofovir for Preventing Hepatocellular Carcinoma in Patients with Chronic Hepatitis B: a Systematic Review and Meta-analysis. Hepatology 2021; 73: 68-78
121 Choi WM, Choi J, Lim YS. Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2021; 19: 246-258.e9
122 Papatheodoridis GV, Dalekos GN, Idilman R. et al Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B. J Hepatol 2020; 73: 1037-1045
123 Voulgaris T, Papatheodoridi M, Lampertico P. et al Clinical utility of hepatocellular carcinoma risk scores in chronic hepatitis B. Liver Int 2020; 40: 484-495
124 Liaw YF, Raptopoulou-Gigi M, Cheinquer H. et al Efficacy and safety of entecavir versus adefovir in chronic hepatitis B patients with hepatic decompensation: A randomized, open-label study. Hepatology 2011; 54: 91-100
125 Shim JH, Lee HC, Kim KM. et al Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. J Hepatol 2010; 52: 176-182
126 Chan HLY, Chen YC, Gane EJ. et al Randomized clinical trial: Efficacy and safety of telbivudine and lamivudine in treatment-naïve patients with HBV-related decompensated cirrhosis. J Viral Hepat 2012; 19: 732-743
127 Liaw YF, Sung JJY, Chow WC. et al Lamivudine for patients with chronic hepatitis B and advanced liver disease. N Engl J Med 2004; 351: 1521-1531
128 Papatheodoridis GV, Dimou E, Dimakopoulos K. et al Outcome of hepatitis B e antigen-negative chronic hepatitis B on long-term nucleos(t)ide analog therapy starting with lamivudine. Hepatology 2005; 42: 121-129
129 Zoulim F, Locarnini S. Hepatitis B Virus Resistance to Nucleos(t)ide Analogues. Gastroenterology 2009; 137: 1593-608.e1–2
130 Warner N, Locarnini S. Mechanisms of hepatitis B virus resistance development. Intervirology 2014; 57: 218-224
131 Berg T, Zoulim F, Moeller B. et al Long-term efficacy and safety of emtricitabine plus tenofovir DF vsß. tenofovir DF monotherapy in adefovir-experienced chronic hepatitis B patients. J Hepatol 2014; 60: 715-722
132 Lim YS, Yoo BC, Byun KS. et al Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: Results of a randomised trial. Gut 2016; 65: 1042-1051
133 Tenney DJ, Rose RE, Baldick CJ. et al Two-year assessment of entecavir resistance in lamivudine-refractory hepatitis B virus patients reveals different clinical outcomes depending on the resistance substitutions present. Antimicrob Agents Chemother 2007; 51: 902-911
134 Cathcart AL, Lik-Yuen Chan H, Bhardwaj N. et al No resistance to tenofovir alafenamide detected through 96 weeks of treatment in patients with chronic hepatitis b infection. Antimicrob Agents Chemother 2018; 62: e01064-18
135 Agarwal K, Brunetto M, Seto WK. et al 96 weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. J Hepatol 2018; 68: 672-681
136 Buti M, Gane E, Seto WK. et al Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1: 196-206
137 Chan HLY, Fung S, Seto WK. et al Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. Lancet Gastroenterol Hepatol 2016; 1: 185-195
138 Lampertico P, Chan HLY, Janssen HLA. et al Review article: long-term safety of nucleoside and nucleotide analogues in HBV-monoinfected patients. Aliment Pharmacol Ther 2016; 44: 16-34
139 Gane EJ, Deray G, Liaw YF. et al Telbivudine improves renal function in patients with chronic hepatitis b. Gastroenterology 2014; 146: 138-146.e5
140 Cholongitas E, Vasiliadis T, Goulis I. et al Telbivudine is associated with improvement of renal function in patients transplanted for HBV liver disease. J Viral Hepat 2015; 22: 574-580
141 Ha NB, Ha NB, Garcia RT. et al Renal dysfunction in chronic hepatitis B patients treated with adefovir dipivoxil. Hepatology 2009; 50: 727-734
142 Buti M, Fung S, Gane E. et al Long-term clinical outcomes in cirrhotic chronic hepatitis B patients treated with tenofovir disoproxil fumarate for up to 5 years. Hepatol Int 2015; 9: 243-250
143 Chang TT, Lai CL, Yoon SK. et al Entecavir treatment for up to 5 years in patients with hepatitis b e antigen-positive chronic hepatitis B. Hepatology 2010; 51: 422-430
144 Tenney DJ, Rose RE, Baldick CJ. et al Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naïve patients is rare through 5 years-of therapy. Hepatology 2009; 49: 1503-1514
145 Hui AY, Chan HLY, Cheung AYK. et al Systematic review: Treatment of chronic hepatitis B virus infection by pegylated interferon. Aliment Pharmacol Ther 2005; 22: 519-528
146 Liaw YF, Jia JD, Chan HLY. et al Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology 2011; 54: 1591-1599
147 Sonneveld MJ, Hansen BE, Piratvisuth T. et al Response-guided peginterferon therapy in hepatitis B e antigen-positive chronic hepatitis B using serum hepatitis B surface antigen levels. Hepatology 2013; 58: 872-880
148 Chan HLY, Messinger D, Papatheodoridis GV. et al A baseline tool for predicting response to peginterferon alfa-2a in HBeAg-positive patients with chronic hepatitis B. Aliment Pharmacol Ther 2018; 48: 547-555
149 Rijckborst V, Hansen BE, Ferenci P. et al Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56: 1006-1011
150 Colombatto P, Oliveri F, Leandro G. et al Platelet and white blood cell counts during therapy with different types of alpha interferon in patients with chronic viral hepatitis. Ital J Gastroenterol Hepatol 1997; 29: 441-447
151 de Andrade LJO, D’Oliveira A, Silva CAC. et al A meta-analysis of patients with chronic hepatitis C treated with interferon-alpha to determine the risk of autoimmune thyroiditis. Acta Gastroenterol Latinoam 2011; 41: 104-110
152 ter Borg MJ, Hansen BE, Bigot G. et al ALT and viral load decline during PEG-IFN alpha-2b treatment for HBeAg-positive chronic hepatitis B. J Clin Virol 2008; 42: 160-164
153 Wong GLH, Wong VWS, Chan HLY. Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B. J Viral Hepat 2014; 21: 825-834
154 Marcellin P, Ahn SH, Ma X. et al Combination of Tenofovir Disoproxil Fumarate and Peginterferon α-2a Increases Loss of Hepatitis B Surface Antigen in Patients with Chronic Hepatitis B. Gastroenterology 2016; 150: 134-144.e10
155 Qiu K, Liu B, Li SY. et al Systematic review with meta-analysis: combination treatment of regimens based on pegylated interferon for chronic hepatitis B focusing on hepatitis B surface antigen clearance. Aliment Pharmacol Ther 2018; 47: 1340-1348
156 Hongthanakorn C, Chotiyaputta W, Oberhelman K. et al Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology 2011; 53: 1854-1863
157 Yeo YH, Ho HJ, Yang HI. et al Factors Associated With Rates of HBsAg Seroclearance in Adults With Chronic HBV Infection: A Systematic Review and Meta-analysis. Gastroenterology 2019; 156: 635-646.e9
158 Sheppard-Law S, Zablotska-Manos I, Kermeen M. et al Factors associated with HBV virological breakthrough. Antivir Ther 2017; 22: 53-60
159 van Vlerken LG, Arends P, Lieveld FI. et al Real life adherence of chronic hepatitis B patients to entecavir treatment. Dig Liver Dis 2015; 47: 577-583
160 Lim YS, Gwak GY, Choi J. et al Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. J Hepatol 2019; 71: 35-44
161 Shirvani-Dastgerdi E, Winer BY, Celià-Terrassa T. et al Selection of the highly replicative and partially multidrug resistant rtS78T HBV polymerase mutation during TDF-ETV combination therapy. J Hepatol 2017; 67: 246-254
162 Park ES, Lee AR, Kim DH. et al Identification of a quadruple mutation that confers tenofovir resistance in chronic hepatitis B patients. J Hepatol 2019; 70: 1093-1102
163 Lin Y, Pan F, Wang Y. et al Adefovir dipivoxil-induced Fanconi syndrome and its predictive factors: A study of 28 cases. Oncol Lett 2017; 13: 307-314
164 Seto WK, Asahina Y, Brown TT. et al Improved Bone Safety of Tenofovir Alafenamide Compared to Tenofovir Disoproxil Fumarate Over 2 Years in Patients With Chronic HBV Infection. Clin Gastroenterol Hepatol 2018 Jun 20: S1542-3565(18)30633-5
165 Fong TL, Lee BT, Tien A. et al Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide. J Viral Hepat 2019; 26: 561-567
166 Grossi G, Loglio A, Facchetti F. et al Tenofovir alafenamide as a rescue therapy in a patient with HBV-cirrhosis with a history of Fanconi syndrome and multidrug resistance. J Hepatol 2018; 68: 195-198
167 Lim SG, Wai CT, Rajnakova A. et al Fatal hepatitis B reactivation following discontinuation of nucleoside analogues for chronic hepatitis B. Gut 2002; 51: 597-599
168 Papatheodoridis G, Vlachogiannakos I, Cholongitas E. et al Discontinuation of oral antivirals in chronic hepatitis B: A systematic review. Hepatology 2016; 63: 1481-1492
169 Chang ML, Liaw YF, Hadziyannis SJ. Systematic review: Cessation of long-term nucleos(t)ide analogue therapy in patients with hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2015; 42: 243-257
170 Raimondo G, Locarnini S, Pollicino T. et al Update of the statements on biology and clinical impact of occult hepatitis B virus infection. J Hepatol 2019; 71: 397-408
171 Perrillo RP, Gish R, Falck-Ytter YT. American Gastroenterological Association Institute technical review on prevention and treatment of hepatitis b virus reactivation during immunosuppressive drug therapy. Gastroenterology 2015; 148: 221-244.e3
172 Yip TCF, Wong GLH, Wong VWS. et al Durability of hepatitis B surface antigen seroclearance in untreated and nucleos(t)ide analogue-treated patients. J Hepatol 2018; 68: 63-72
173 Stelma F, van der Ree MH, Jansen L. et al HBsAg loss after peginterferon-nucleotide combination treatment in chronic hepatitis B patients: 5 years of follow-up. J Viral Hepat 2017; 24: 1107-1113
174 Roushan MRH, Mohammadpour M, Baiany M. et al Time to seroconversion of HBsAg to anti-HBs in individuals who lost HBsAg during follow-up. Epidemiol Infect 2016; 144: 2648-2653
175 Chaung KT, Ha NB, Trinh HN. et al High frequency of recurrent viremia after hepatitis B e antigen seroconversion and consolidation therapy. J Clin Gastroenterol 2012; 46: 865-870
176 Fung J, Lai CL, Tanaka Y. et al The duration of lamivudine therapy for chronic hepatitis b: Cessation vs. continuation of treatment after HBeAg seroconversion. Am J Gastroenterol 2009; 104: 1940-1946
177 Qiu YW, Huang LH, Yang WL. et al Hepatitis B surface antigen quantification at hepatitis B e antigen seroconversion predicts virological relapse after the cessation of entecavir treatment in hepatitis B e antigen-positive patients. Int J Infect Dis 2016; 43: 43-48
178 Chi H, Hansen BE, Yim C. et al Reduced risk of relapse after long-term nucleos(t)ide analogue consolidation therapy for chronic hepatitis B. Aliment Pharmacol Ther 2015; 41: 867-876
179 Chen YC, Peng CY, Jeng WJ. et al Clinical outcomes after interruption of entecavir therapy in HBeAg-negative chronic hepatitis B patients with compensated cirrhosis. Aliment Pharmacol Ther 2015; 42: 1182-1191
180 Jung KS, Park JY, Chon YE. et al Clinical outcomes and predictors for relapse after cessation of oral antiviral treatment in chronic hepatitis B patients. J Gastroenterol 2016; 51: 830-839
181 Berg T, Simon KG, Mauss S. et al Long-term response after stopping tenofovir disoproxil fumarate in non-cirrhotic HBeAg-negative patients – FINITE study. J Hepatol 2017; 67: 918-924
182 Jeng WJ, Chen YC, Sheen IS. et al Clinical Relapse After Cessation of Tenofovir Therapy in Hepatitis B e Antigen–Negative Patients. Clin Gastroenterol Hepatol 2016; 14: 1813-1820.e1
183 Höner zu Siederdissen C, Hui AJ, Sukeepaisarnjaroen W. et al Contrasting timing of virological relapse after discontinuation of tenofovir or entecavir in Hepatitis B e antigen-negative patients. J Infect Dis 2018; 218: 1480-1484
184 Su TH, Yang HC, Tseng TC. et al Distinct Relapse Rates and Risk Predictors after Discontinuing Tenofovir and Entecavir Therapy. J Infect Dis 2018; 217: 1193-1201
185 Kuo MTe, Hu TH, Hung CH. et al Hepatitis B virus relapse rates in chronic hepatitis B patients who discontinue either entecavir or tenofovir. Aliment Pharmacol Ther 2019; 49: 218-228
186 Höner Zu Siederdissen C, Rinker F, Maasoumy B. et al Viral and host responses after stopping long-term Nucleos(t)ide analogue therapy in HBeAg-negative chronic Hepatitis B. J Infect Dis 2016; 214: 1492-1497
187 Hadziyannis SJ, Sevastianos V, Rapti I. et al Sustained responses and loss of HBsAg in HBeAg-negative patients with chronic hepatitis B who stop long-term treatment with adefovir. Gastroenterology 2012; 143: 629-636.e1
188 Papatheodoridis GV, Rigopoulou EI, Papatheodoridi M. et al Daring-B: Discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B. Antivir Ther 2018; 23: 677-685
189 van Bömmel F, Stein K, Heyne R. et al Response to discontinuation of long-term nucleos(t)ide analogue treatment in HBeAg negative patients: Results of the Stop-NUC trial. J Hepatol 2020; 73: S118-S119
190 Zimmer CL, Rinker F, Höner Zu Siederdissen C. et al Increased NK Cell Function after Cessation of Long-Term Nucleos(t)ide Analogue Treatment in Chronic Hepatitis B Is Associated with Liver Damage and HBsAg Loss. Journal of Infectious Diseases. Oxford University Press; 2018: 1656-1666
191 Rinker F, Zimmer CL, Höner zu Siederdissen C. et al Hepatitis B virus-specific T cell responses after stopping nucleos(t)ide analogue therapy in HBeAg-negative chronic hepatitis B. J Hepatol 2018; 69: 584-593
192 Buster EHCJ, Hansen BE, Buti M. et al Peginterferon alpha-2b is safe and effective in HBeAg-positive chronic hepatitis B patients with advanced fibrosis. Hepatology 2007; 46: 388-394
193 Charatcharoenwitthaya P, Sukeepaisarnjaroen W, Piratvisuth T. et al Treatment outcomes and validation of the stopping rule for response to peginterferon in chronic hepatitis B: A Thai nationwide cohort study. J Gastroenterol Hepatol 2016; 31: 1874-1881
194 Campistol JM, Esforzado N, Martínez J. et al Efficacy and tolerance of interferon-α2b in the treatment of chronic hepatitis C virus infection in haemodialysis patients. Pre- and post-renal transplantation assessment. Nephrol Dial Transplant 1999; 14: 2704-2709
195 Chan TM, Ho SKN, Tang CSO. et al Pilot study of pegylated interferon-alpha 2a in dialysis patients with chronic hepatitis C virus infection. Nephrology 2007; 12: 11-17
196 Coppolino G, Simeoni M, Summaria C. et al The case of chronic hepatitis B treatment with tenofovir: an update for nephrologists. J Nephrol 2015; 28: 393-402
197 Liu J, Wang J, Qi C. et al Baseline hepatitis B virus titer predicts initial postpartum hepatic flare. J Clin Gastroenterol 2018; 52: 902-907
198 Shang J, Wen Q, Wang CC. et al Safety and efficacy of telbivudine for chronic hepatitis B during the entire pregnancy: Long-term follow-up. J Viral Hepat 2017; 24: 43-48
199 Antiretroviral Pregnancy Registry Interim Report for 1 January 1989–31 January 2020*. http://www.apregistry.com. 2020
200 Yang M, Qin Q, Fang Q. et al Cesarean section to prevent mother-to-child transmission of hepatitis B virus in China: A meta-analysis. BMC Pregnancy Childbirth 2017; 17: 303
201 Chen HL, Cai JY, Song YP. et al Vaginal delivery and HBV mother to child transmission risk after immunoprophylaxis: A systematic review and a meta-analysis. Midwifery 2019; 74: 116-125
202 Pan CQ, Zou HB, Chen Y. et al Cesarean section reduces perinatal transmission of hepatitis B virus infection from hepatitis b surface antigen-positive women to their infants. Clin Gastroenterol Hepatol 2013; 11: 1349-1355
203 Wang M, Bian Q, Zhu Y. et al Real-world study of tenofovir disoproxil fumarate to prevent hepatitis B transmission in mothers with high viral load. Aliment Pharmacol Ther 2019; 49: 211-217
204 Hou J, Wang G, Wang F. et al Guideline of Prevention and Treatment for Chronic Hepatitis B (2015 Update). J Clin Transl Hepatol 2017; 5: 297-318
205 Hou J, Cui F, Ding Y. et al Management Algorithm for Interrupting Mother-to-Child Transmission of Hepatitis B Virus. Clin Gastroenterol Hepatol 2019; 17: 1929-1936.e1
206 Ehrhardt S, Xie C, Guo N. et al Breastfeeding while taking lamivudine or tenofovir disoproxil fumarate: A review of the evidence. Clin Infect Dis 2015; 60: 275-278
207 Hu X, Wang L, Xu F. Guides concerning tenofovir exposure via breastfeeding: A comparison of drug dosages by developmental stage. Int J Infect Dis 2019; 87: 8-12
208 Mofenson LM, Baggaley RC, Mameletzis I. Tenofovir disoproxil fumarate safety for women and their infants during pregnancy and breastfeeding. Aids 2017; 31: 213-232
209 Mugwanya KK, John-Stewart G, Baeten J. Safety of oral tenofovir disoproxil fumarate-based HIV pre-exposure prophylaxis use in lactating HIV-uninfected women. Expert Opin Drug Saf 2017; 16: 867-871
210 Shi Z, Yang Y, Wang H. et al Breastfeeding of newborns by mothers carrying hepatitis B virus: A meta-analysis and systematic review. Arch Pediatr Adolesc Med 2011; 165: 837-846
211 Paul S, Dickstein A, Saxena A. et al Role of surface antibody in hepatitis B reactivation in patients with resolved infection and hematologic malignancy: A meta-analysis. Hepatology 2017; 66: 379-388
212 Pérez-Alvarez R, Díaz-Lagares C, García-Hernández F. et al Hepatitis B Virus (HBV) Reactivation in Patients Receiving Tumor Necrosis Factor (TNF)-Targeted Therapy. Medicine (Baltimore) 2011; 90: 359-371
213 Voican CS, Mir O, Loulergue P. et al Hepatitis B virus reactivation in patients with solid tumors receiving systemic anticancer treatment. Ann Oncol 2016; 27: 2172-2184
214 Mallet V, van Bömmel F, Doerig C. et al Management of viral hepatitis in patients with haematological malignancy and in patients undergoing haemopoietic stem cell transplantation: Recommendations of the 5th European Conference on Infections in Leukaemia (ECIL-5). Lancet Infect Dis 2016; 16: 606-617
215 Barone M, Notarnicola A, Lopalco G. et al Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection. Hepatology 2015; 62: 40-46
216 Caocci G, Murgia F, Podda L. et al Reactivation of hepatitis B virus infection following ruxolitinib treatment in a patient with myelofibrosis. Leukemia 2014; 28: 225-227
217 Kirito K, Sakamoto M, Enomoto N. Elevation of the hepatitis b virus dna during the treatment of polycythemia vera with the JAK kinase inhibitor ruxolitinib. Intern Med 2016; 55: 1341-1344
218 Godbert B, Petitpain N, Lopez A. et al Hepatitis B reactivation and immune check point inhibitors. Dig Liver Dis 2021; 53: 452-455
219 Lee PC, Chao Y, Chen MH. et al Risk of HBV reactivation in patients with immune checkpoint inhibitor-treated unresectable hepatocellular carcinoma. J Immunother Cancer 2020; 8: 1072
220 Ekpanyapong S, Reddy KR. Hepatitis B Virus Reactivation: What Is the Issue, and How Should It Be Managed?. Clin Liver Dis 2020; 24: 317-333
221 Gane E, Verdon DJ, Brooks AE. et al Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study. J Hepatol 2019; 71: 900-907
222 Jang JW, Kim YW, Lee SW. et al Reactivation of hepatitis B virus in HBsAg-negative patients with hepatocellular carcinoma. PLoS One 2015; 10: e0122041
223 Lao XM, Luo G, Ye LT. et al Effects of antiviral therapy on hepatitis B virus reactivation and liver function after resection or chemoembolization for hepatocellular carcinoma. Liver Int 2013; 33: 595-604
224 Huang S, Xia Y, Lei Z. et al Antiviral Therapy Inhibits Viral Reactivation and Improves Survival after Repeat Hepatectomy for Hepatitis B Virus-Related Recurrent Hepatocellular Carcinoma. J Am Coll Surg 2017; 224: 283-293.e4
225 Yoo SH, Jang JW, Kwon JH. et al Preemptive antiviral therapy with entecavir can reduce acute deterioration of hepatic function following transarterial chemoembolization. Clin Mol Hepatol 2016; 22: 458-465
226 Huang H, Li X, Zhu J. et al Entecavir vs lamivudine for prevention of hepatitis B virus reactivation among patients with untreated diffuse large B-cell lymphoma receiving R-CHOP chemotherapy: A randomized clinical trial. JAMA – J Am Med Assoc 2014; 312: 2521-2530
227 Zhang MY, Zhu GQ, Shi KQ. et al Systematic review with network meta-analysis: Comparative efficacy of oral nucleos(t)ide analogues for the prevention of chemotherapy-induced hepatitis B virus reactivation. Oncotarget 2016; 7: 30642-30658
228 Grossi G, Viganò M, Facchetti F. et al Failure of long-term lamivudine prophylaxis in patients with resolved hepatitis B infection undergoing chemotherapy and allogenic hematopoietic stem cell transplantation for hematological malignancies: Two case reports. Haematologica 2017; 102: e423-e426
229 Buti M, Manzano ML, Morillas RM. et al Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLoS One 2017; 12: e0184550
230 Nakaya A, Fujita S, Satake A. et al Delayed HBV reactivation in rituximab-containing chemotherapy: How long should we continue anti-virus prophylaxis or monitoring HBV-DNA?. Leuk Res 2016; 50: 46-49
231 Liaw YF, Sheen IS, Lee CM. et al Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease. Hepatology 2011; 53: 62-72
232 Jang JW, Choi JY, Kim YS. et al Long-term effect of antiviral therapy on disease course after decompensation in patients with hepatitis B virus-related cirrhosis. Hepatology 2015; 61: 1809-1820
233 Peng CY, Chien RN, Liaw YF. Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy. J Hepatol 2012; 57: 442-450
234 Burra P, Germani G, Adam R. et al Liver transplantation for HBV-related cirrhosis in Europe: An ELTR study on evolution and outcomes. J Hepatol 2013; 58: 287-296
235 De Simone P, Romagnoli R, Tandoi F. et al Early introduction of subcutaneous hepatitis B immunoglobulin following liver transplantation for hepatitis B virus infection: A prospective, multicenter study. Transplantation 2016; 100: 1507-1512
236 Zheng JN, Zou TT, Zou H. et al Comparative efficacy of oral nucleotide analogues for the prophylaxis of hepatitis B virus recurrence after liver transplantation: a network meta-analysis. Expert Rev Anti Infect Ther 2016; 14: 979-987
237 Fernández I, Loinaz C, Hernández O. et al Tenofovir/entecavir monotherapy after hepatitis B immunoglobulin withdrawal is safe and effective in the prevention of hepatitis B in liver transplant recipients. Transpl Infect Dis 2015; 17: 695-701
238 Choudhary NS, Saraf N, Saigal S. et al Low-dose short-term hepatitis B immunoglobulin with high genetic barrier antivirals: The ideal post-transplant hepatitis B virus prophylaxis?. Transpl Infect Dis 2015; 17: 329-333
239 Cholongitas E, Papatheodoridis GV. High genetic barrier nucleos(t)ide analogue(s) for prophylaxis from hepatitis b virus recurrence after liver transplantation: A systematic review. Am J Transplant 2013; 13: 353-362
240 Manini MA, Whitehouse G, Bruce M. et al Entecavir or tenofovir monotherapy prevents HBV recurrence in liver transplant recipients: A 5-year follow-up study after hepatitis B immunoglobulin withdrawal. Dig Liver Dis 2018; 50: 944-953
241 Sripongpun P, Mannalithara A, Kwo PY. et al Potential Benefits of Switching Liver Transplant Recipients to Tenofovir Alafenamide Prophylaxis. Clin Gastroenterol Hepatol 2020; 18: 747-749
242 Weber NK, Forman LM, Trotter JF. HBIg discontinuation with maintenance oral anti-viral therapy and HBV vaccination in liver transplant recipients. Dig Dis Sci 2010; 55: 505-509
243 Wong SN, Chu CJ, Wai CT. et al Low risk of hepatitits B virus recurrence after withdrawal of long-term hepatitis B immunoglobulin in patients receiving maintenance nucleos(t)ide analogue therapy. Liver Transplant 2007; 13: 374-381
244 Fung J, Chan SC, Cheung C. et al Oral nucleoside/nucleotide analogs without hepatitis b immune globulin after liver transplantation for hepatitis b. Am J Gastroenterol 2013; 108: 942-948
245 Terrault N. Editorial: Prophylaxis in hbv-infected liver transplant patients: End of the HBIG era?. Am J Gastroenterol 2013; 108: 949-951
246 Wang P, Tam N, Wang H. et al Is hepatitis B immunoglobulin necessary in prophylaxis of hepatitis B recurrence after liver transplantation? A meta-analysis. PLoS One 2014; 9: e104480
247 Lens S, García-Eliz M, Fernández I. et al Shorter hepatitis B immunoglobulin administration is not associated to hepatitis B virus recurrence when receiving combined prophylaxis after liver transplantation. Liver Int 2018; 38: 1940-1950
248 Idilman R, Akyildiz M, Keskin O. et al The long-term efficacy of combining nucleos(t)ide analog and low-dose hepatitis B immunoglobulin on post-transplant hepatitis B virus recurrence. Clin Transplant 2016; 30: 1216-1221
249 Cholongitas E, Goulis I, Antoniadis N. et al Nucleos(t)ide analog(s) prophylaxis after hepatitis B immunoglobulin withdrawal against hepatitis B and D recurrence after liver transplantation. Transpl Infect Dis 2016; 18: 667-673
250 Fox AN, Terrault NA. Individualizing hepatitis B infection prophylaxis in liver transplant recipients. J Hepatol 2011; 55: 507-509
251 Karlas T, Hartmann J, Weimann A. et al Prevention of lamivudine-resistant hepatitis B recurrence after liver transplantation with entecavir plus tenofovir combination therapy and perioperative hepatitis B immunoglobulin only. Transpl Infect Dis 2011; 13: 299-302
252 Roche B, Samuel D. Liver transplantation in delta virus infection. Semin Liver Dis 2012; 32: 245-255
253 Kasraianfard A, Watt KD, Lindberg L. et al HBIG Remains Significant in the Era of New Potent Nucleoside Analogues for Prophylaxis Against Hepatitis B Recurrence After Liver Transplantation. Int Rev Immunol 2016; 35: 312-324
254 Radhakrishnan K, Chi A, Quan DJ. et al Short course of postoperative hepatitis B immunoglobulin plus antivirals prevents reinfection of liver transplant recipients. Transplantation 2017; 101: 2079-2082
255 Teperman LW, Poordad F, Bzowej N. et al Randomized trial of emtricitabine/tenofovir disoproxil fumarate after hepatitis B immunoglobulin withdrawal after liver transplantation. Liver Transplant 2013; 19: 594-601
256 Stärkel P, Stoffel M, Lerut J. et al Response to an experimental HBV vaccine permits withdrawal of HBIg prophylaxis in fulminant and selected chronic HBV-infected liver graft recipients. Liver Transplant 2005; 11: 1228-1234
257 Sanchez-Fueyo A, Rimola A, Grande L. et al Hepatitis B immunoglobulin discontinuation followed by hepatitis B virus vaccination: A new strategy in the prophylaxis of hepatitis B virus recurrence after liver transplantation. Hepatology 2000; 31: 496-501
258 Rosenau J, Hooman N, Rifai K. et al Hepatitis B virus immunization with an adjuvant containing vaccine after liver transplantation for hepatitis B-related disease: Failure of humoral and cellular immune response. Transpl Int 2006; 19: 828-833
259 Margreiter R, Kramar R, Huber C. et al Combined Liver and Kidney Transplantation. Lancet 1984; 323: 1077-1078
260 Ruiz R, Kunitake H, Wilkinson AH. et al Long-term analysis of combined liver and kidney transplantation at a single center. Arch Surg 2006; 141: 735-741
261 Kirchner GI, Rifai K, Cantz T. et al Outcome and quality of life in patients with polycystic liver disease after liver or combined liver-kidney transplantation. Liver Transplant 2006; 12: 1268-1277
262 Jalanko H, Pakarinen M. Combined liver and kidney transplantation in children. Pediatr Nephrol 2014; 29: 805-814
263 Pöge U, Gerhardt T, Palmedo H. et al MDRD equations for estimation of GFR in renal transplant recipients. Am J Transplant 2005; 5: 1306-1311
264 Neumann UP, Lang M, Moloenhauer A. et al Significance of a T-lymphocytotoxic crossmatch in liver and combined liver-kidney transplantation. Transplantation 2001; 71: 1163-1168
265 Olausson M, Mjörnstedt L, Nordén G. et al Successful combined partial auxiliary liver and kidney transplantation in highly sensitized cross-match positive recipients. Am J Transplant 2007; 7: 130-136
266 Hwang JP, Lok ASF. Management of patients with hepatitis B who require immunosuppressive therapy. Nat Rev Gastroenterol Hepatol 2014; 11: 209-219
267 Kanaan N, Kabamba B, Maréchal C. et al Significant rate of hepatitis B reactivation following kidney transplantation in patients with resolved infection. J Clin Virol 2012; 55: 233-238
268 Loomba R, Liang TJ. Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology 2017; 152: 1297-1309
269 Shang J, Wang H, Sun J. et al A comparison of lamivudine vs entecavir for prophylaxis of hepatitis B virus reactivation in allogeneic hematopoietic stem cell transplantation recipients: A single-institutional experience. Bone Marrow Transplant 2016; 51: 581-586
270 Seto WK, Chan TSY, Hwang YY. et al Hepatitis B reactivation in occult viral carriers undergoing hematopoietic stem cell transplantation: A prospective study. Hepatology 2017; 65: 1451-1461
271 O’Grady J. The immunoreactive patient: Rejection and autoimmune disease. Liver Transplant 2011; 17 (Suppl. 03) S29-S33
272 Skagen CL, Jou JH, Said A. Risk of de novo hepatitis in liver recipients from hepatitis-B core antibody-positive grafts – a systematic analysis. Clin Transplant 2011; 25: E243-E249
273 Huprikar S, Danziger-Isakov L, Ahn J. et al Solid organ transplantation from hepatitis B virus-positive donors: Consensus guidelines for recipient management. Am J Transplant 2015; 15: 1162-1172
274 Wright AJ, Fishman JA, Chung RT. Lamivudine compared with newer antivirals for prophylaxis of hepatitis B core antibody positive livers: A cost-effectiveness analysis. Am J Transplant 2014; 14: 629-634
275 Chang MS, Olsen SK, Pichardo EM. et al Prevention of de novo hepatitis B in recipients of core antibody-positive livers with lamivudine and other nucleos(t)ides: A 12-year experience. Transplantation 2013; 95: 960-965
276 Chotiyaputta W, Pelletier SJ, Fontana RJ. et al Long-term efficacy of nucleoside monotherapy in preventing HBV infection in HBsAg-negative recipients of anti-HBc-positive donor livers. Hepatol Int 2010; 4: 707-715
277 Leong J, Coty P, Isabel Fiel M. et al Lamivudine resistance leading to de novo hepatitis B infection in recipients of hepatitis B core antibody positive liver allografts. Hepatol Res 2014; 44: 1248-1252
278 Yamashiki N, Yoshizawa A, Ueda Y. et al The use of hepatitis B immunoglobulin with or without hepatitis B vaccine to prevent de novo hepatitis B in pediatric recipients of anti-HBc–positive livers. Pediatr Transplant 2018; 22: e13227
279 Yang A, Guo Z, Ren Q. et al Active immunization in patients transplanted for hepatitis B virus related liver diseases: A prospective study. PLoS One 2017; 12: e0188190
280 Wang SH, Loh PY, Lin TL. et al Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen–positive graft. Liver Transplant 2017; 23: 1266-1272
281 Yoshizawa A, Yamashiki N, Ueda Y. et al Long-term efficacy of hepatitis B vaccination as post-transplant prophylaxis in hepatitis B surface antigen (HBsAg) positive recipients and HBsAg negative recipients of anti-hepatitis B core positive grafts. Hepatol Res 2016; 46: 541-551
282 Verna EC. Vaccination to prevent de novo hepatitis B: Are there patients who do not need antiviral prophylaxis?. Liver Transplant 2017; 23: 1253-1254
283 Mahboobi N, Tabatabaei SV, Blum HE. et al Renal grafts from anti-hepatitis B core-positive donors: A quantitative review of the literature. Transpl Infect Dis 2012; 14: 445-451
284 Manickam P, Krishnamoorthi R, Kanaan Z. et al Prognostic implications of recipient or donor hepatitis B seropositivity in thoracic transplantation: Analysis of 426 hepatitis B surface antigen-positive recipients. Transpl Infect Dis 2014; 16: 597-604
285 Satterthwaite R, Ozgu I, Shidban H. et al Risks of transplanting kidneys from hepatitis B surface antigen- negative, hepatitis B core antibody-positive donors. Transplantation 1997; 64: 432-435
286 Yu S, Yu J, Zhang W. et al Safe use of liver grafts from hepatitis B surface antigen positive donors in liver transplantation. J Hepatol 2014; 61: 809-815
287 Saidi RF, Jabbour N, Shah SA. et al Liver transplantation from hepatitis B surface antigen-positive donors. Transplant Proc 2013; 45: 279-280
288 Chancharoenthana W, Townamchai N, Pongpirul K. et al The outcomes of kidney transplantation in hepatitis B surface antigen (HBsAg)-negative recipients receiving graft from HBsAg-positive donors: A retrospective, propensity score-matched study. Am J Transplant 2014; 14: 2814-2820
289 Jiang H, Wu J, Zhang X. et al Kidney transplantation from hepatitis B surface antigen positive donors into hepatitis B surface antibody positive recipients: A prospective nonrandomized controlled study from a single center. Am J Transplant 2009; 9: 1853-1858
290 Magiorkinis E, Paraskevis D, Pavlopoulou ID. et al Renal transplantation from hepatitis B surface antigen (HBsAg)-positive donors to HBsAg-negative recipients: A case of post-transplant fulminant hepatitis associated with an extensively mutated hepatitis B virus strain and review of the current literature. Transpl Infect Dis 2013; 15: 393-399
291 Giaccone L, Festuccia M, Marengo A. et al Hepatitis B Virus Reactivation and Efficacy of Prophylaxis with Lamivudine in Patients Undergoing Allogeneic Stem Cell Transplantation. Biol Blood Marrow Transplant 2010; 16: 809-817
292 Lau GKK, Lie AKW, Kwong YL. et al A case-controlled study on the use of HBsAg-positive donors for allogeneic hematopoietic cell transplantation. Blood 2000; 96: 452-458
293 Hui CK, Lie A, Au WY. et al Effectiveness of prophylactic anti-HBV therapy in allogeneic hematopoietic stem cell transplantation with HBsAg positive donors. Am J Transplant 2005; 5: 1437-1445
294 Franchello A, Ghisetti V, Marzano A. et al Transplantation of hepatitis B surface antigen-positive livers into hepatitis B virus-positive recipients and the role of hepatitis delta coinfection. Liver Transplant 2005; 11: 922-928
295 Su WJ, Ho MC, Ni YH. et al High-titer antibody to hepatitis b surface antigen before liver transplantation can prevent de novo hepatitis b infection. J Pediatr Gastroenterol Nutr 2009; 48: 203-208
296 Kim KH, Sang HA, Hyo YC. et al Hepatitis B virus infection after renal transplantation in the presence of antibody to hepatitis B surface antigen immunity. J Gastroenterol Hepatol 2004; 19: 847-853
297 Gutierrez Domingo I, Pascasio Acevedo JM, Alcalde Vargas A. et al Response to vaccination against hepatitis B virus with a schedule of four 40-μg doses in cirrhotic patients evaluated for liver transplantation: Factors associated with a response. In: Transplantation Proceedings 2012: 1499-1501
298 Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO). Epidemiol Bull 2020; 34. Im Internet: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2020/Ausgaben/34_20.pdf?__blob=publicationFile
299 Hilgendorf I, Freund M, Jilg W. et al Vaccination of allogeneic haematopoietic stem cell transplant recipients: Report from the International Consensus Conference on Clinical Practice in chronic GVHD. Vaccine 2011; 29: 2825-2833
300 Kim DK, Riley LE, Harriman KH. et al Advisory Committee on Immunization Practices Recommended Immunization Schedule for Adults Aged 19 Years or Older – United States, 2017. MMWR Morb Mortal Wkly Rep 2017; 66: 136-138
301 Sawyer MH, Hoerger TJ, Murphy TV. et al Use of hepatitis B vaccination for adults with diabetes mellitus: Recommendations of the advisory committee on immunization practices (ACIP). Morb Mortal Wkly Rep 2011; 60: 1709-1711
302 World Health Organization. Global health sector strategy on viral hepatitis 2016-2021. Glob Hepat Program Dep HIV/AIDS; 2016: 56
303 Poethko-Müller C, Zimmermann R, Hamouda O. et al Die Seroepidemiologie der Hepatitis A, B und C in Deutschland: Ergebnisse der Studie zur Gesundheit Erwachsener in Deutschland (DEGS1). Bundesgesundheitsblatt – Gesundheitsforsch – Gesundheitsschutz 2013; 56: 707-715
304 Heidrich B, Cetindere A, Beyaz M. et al High prevalence of hepatitis markers in immigrant populations: A prospective screening approach in a real-world setting. Eur J Gastroenterol Hepatol 2014; 26: 1090-1097
305 Centers for Disease Control and Prevention. Immunization of Health-Care Personnel Recommendations of the Advisory Committee on Immunization Practices (ACIP) Morbidity and Mortality Weekly Report. Mmwr 2011; 60: 1-46 . Im Internet: http://www.cdc.gov/mmwr/cme/conted.html
306 Huzly D, Schenk T, Jilg W. et al Comparison of nine commercially available assays for quantification of antibody response to hepatitis B virus surface antigen. J Clin Microbiol 2008; 46: 1298-1306
307 Brunskole Hummel I, Huber B, Wenzel JJ. et al Markers of protection in children and adolescents six to fourteen years after primary hepatitis B vaccination in real life: A pilot study. Pediatr Infect Dis J 2016; 35: 286-291
308 Schönberger K, Riedel C, Rückinger S. et al Determinants of long-term protection after hepatitis b vaccination in infancy: A meta-analysis. Pediatr Infect Dis J 2013; 32: 307-313
309 Chiara F, Bartolucci GB, Mongillo M. et al Hepatitis B vaccination at three months of age: A successful strategy?. Vaccine 2013; 31: 1696-1700
310 Middleman AB, Baker CJ, Kozinetz CA. et al Duration of protection after infant hepatitis B vaccination series. Pediatrics 2014; 133: e1500-e1507
311 Dini G, Toletone A, Barberis I. et al Persistence of protective anti-HBs antibody levels and anamnestic response to HBV booster vaccination: A cross-sectional study among healthcare students 20 years following the universal immunization campaign in Italy. Hum Vaccines Immunother 2017; 13: 440-444
312 Bruce MG, Bruden D, Hurlburt D. et al Antibody Levels and Protection after Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. J Infect Dis 2016; 214: 16-22
313 Harder T, Remschmidt C, Falkenhorst G. et al Background paper to the revised recommendation for hepatitis B vaccination of persons at particular risk and for hepatitis B postexposure prophylaxis in Germany. Bundesgesundheitsblatt – Gesundheitsforsch – Gesundheitsschutz 2013; 56: 1565-1576
314 FitzSimons D, Hendrickx G, Vorsters A. et al Hepatitis B vaccination: A completed schedule enough to control HBV lifelong?. Milan, Italy, 17–18 November 2011. Vaccine 2013; 31: 584-590
315 World Health Organization. Weekly epidemiological record. Wkly Epidemiol Rec 2009; 84, 40: 405-420
316 Werner JM, Abdalla A, Gara N. et al The hepatitis B vaccine protects re-exposed health care workers, but does not provide sterilizing immunity. Gastroenterology 2013; 145: 1026-1034
317 David MC, Ha SH, Paynter S. et al A systematic review and meta-analysis of management options for adults who respond poorly to hepatitis B vaccination. Vaccine 2015; 33: 6564-6569
318 Robert Koch-Institut. Epidemiologisches Bulletin. Epidemiol Bull 2013; 36/37: 371-381 . Im Internet: https://www.rki.de/DE/Content/Infekt/EpidBull/Archiv/2013/Ausgaben/36_37_13.pdf?__blob=publicationFile
319 Stramer SL, Wend U, Candotti D. et al Nucleic acid testing to detect HBV infection in blood donors. N Engl J Med 2011; 364: 236-247
320 Launay O, Rosenberg AR, Rey D. et al Long-term Immune Response to Hepatitis B Virus Vaccination Regimens in Adults With Human Immunodeficiency Virus 1 Secondary Analysis of a Randomized Clinical Trial. JAMA Intern Med 2016; 176: 603-610
321 Robert Koch-Institut. Empfehlungen der Ständigen Impfkommission (STIKO) am Robert Koch-Institut. Epidemiol Bull 2017; 34: 333-376
322 Mouchet J, Salvo F, Raschi E. et al Hepatitis B vaccination and the putative risk of central demyelinating diseases – A systematic review and meta-analysis. Vaccine 2018; 36: 1548-1555
323 Vogel G. Europe’s top court alarms vaccine experts. Science (80-) 2017; 356: 1320
324 Mertens T. GfV-Stellungnahme zum EU-Urteil HBV-Impfung-MS-3-2017-06-23. Online 2017; Im Internet: https://www.g-f-v.org/node/716
325 Sheffield JS, Hickman A, Tang J. et al Efficacy of an accelerated hepatitis b vaccination program during pregnancy. Obstet Gynecol 2011; 117: 1130-1135
326 Raven SFH, De Heus B, Wong A. et al Fluctuation of Viremia in Hepatitis B Virus-Infected Healthcare Workers Performing Exposure-Prone Procedures in the Netherlands. Infect Control Hosp Epidemiol 2016; 37: 655-660
327 Gerlich WH. Prophylactic vaccination against hepatitis B: achievements, challenges and perspectives. Med Microbiol Immunol 2015; 204: 39-55
328 Fattovich G, Boscaro S, Noventa F. et al Influence of Hepatitis Delta Virus Infection on Progression to Cirrhosis in Chronic Hepatitis Type B. J Infect Dis 1987; 155: 931-935
329 Fattovich G, Giustina G, Christensen E. et al Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. Gut 2000; 46: 420-426
330 Miao Z, Zhang S, Ou X. et al Estimating the Global Prevalence, Disease Progression, and Clinical Outcome of Hepatitis Delta Virus Infection. J Infect Dis 2020; 221: 1677-1687
331 Stockdale AJ, Kreuels B, Henrion MYR. et al The global prevalence of hepatitis D virus infection: Systematic review and meta-analysis. J Hepatol 2020; 73: 523-532
332 Alfaiate D, Clément S, Gomes D. et al Chronic hepatitis D and hepatocellular carcinoma: A systematic review and meta-analysis of observational studies. J Hepatol 2020; 73: 533-539
333 Le Gal F, Brichler S, Drugan T. et al Genetic diversity and worldwide distribution of the deltavirus genus: A study of 2,152 clinical strains. Hepatology 2017; 66: 1826-1841
334 Su CW, Huang YH, Huo TI. et al Genotypes and Viremia of Hepatitis B and D Viruses Are Associated With Outcomes of Chronic Hepatitis D Patients. Gastroenterology 2006; 130: 1625-1635
335 Spaan M, Carey I, Bruce M. et al Hepatitis delta genotype 5 is associated with favourable disease outcome and better response to treatment compared to genotype 1. J Hepatol 2020; 72: 1097-1104
336 Roulot D, Brichler S, Layese R. et al Origin, HDV genotype and persistent viremia determine outcome and treatment response in patients with chronic hepatitis delta. J Hepatol 2020; 73: 1046-1062
337 Wranke A, Wedemeyer H. Antiviral therapy of hepatitis delta virus infection – progress and challenges towards cure. Curr Opin Virol 2016; 20: 112-118
338 Wedemeyer H, Yurdaydìn C, Dalekos GN. et al Peginterferon plus adefovir versus either drug alone for hepatitis delta. N Engl J Med 2011; 364: 322-331
339 Wedemeyer H, Yurdaydin C, Hardtke S. et al PEG-Interferon alfa-2a plus tenofovir disoproxil fumarate for hepatitis D (HIDIT-II): a randomised, placebo controlled, phase 2 trial. Lancet Infect Dis 2019; 19: 275-286
340 Heidrich B, Yurdaydin C, Kabaçam G. et al Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Hepatology 2014; 60: 87-97
341 Yurdaydin C, Keskin O, Kalkan Ç. et al Interferon Treatment Duration in Patients with Chronic Delta Hepatitis and its Effect on the Natural Course of the Disease. Journal of Infectious Diseases 2018; 217: 1184-1192
342 Wranke A, Serrano BC, Heidrich B. et al Antiviral treatment and liver-related complications in hepatitis delta. Hepatology 2017; 65: 414-425
343 Kamal H, Westman G, Falconer K. et al Long-Term Study of Hepatitis Delta Virus Infection at Secondary Care Centers: The Impact of Viremia on Liver-Related Outcomes. Hepatology 2020; 72: 1177-1190
344 Niro GA, Smedile A, Fontana R. et al HBsAg kinetics in chronic hepatitis D during interferon therapy: on-treatment prediction of response. Aliment Pharmacol Ther 2016; 44: 620-628
345 Yurdaydin C, Abbas Z, Buti M. et al Treating chronic hepatitis delta: The need for surrogate markers of treatment efficacy. J Hepatol 2019; 70: 1008-1015
346 Loglio A, Ferenci P, Uceda Renteria SC. et al Excellent safety and effectiveness of high-dose myrcludex-B monotherapy administered for 48 weeks in HDV-related compensated cirrhosis: A case report of 3 patients. J Hepatol 2019; 71: 834-839
347 Keskin O, Wedemeyer H, Tüzün A. et al Association Between Level of Hepatitis D Virus RNA at Week 24 of Pegylated Interferon Therapy and Outcome. Clin Gastroenterol Hepatol 2015; 13: 2342-2349.e2
348 Heller T, Rotman Y, Koh C. et al Long-term therapy of chronic delta hepatitis with peginterferon alfa. Aliment Pharmacol Ther 2014; 40: 93-104
349 Yurdaydin C, Bozkaya H, Gürel S. et al Famciclovir treatment of chronic delta hepatitis. J Hepatol 2002; 37: 266-271
350 Niro GA, Ciancio A, Tillman HL. et al Lamivudine therapy in chronic delta hepatitis: A multicentre randomized-controlled pilot study. Aliment Pharmacol Ther 2005; 22: 227-232
351 Kabaçam G, Önder FO, Yakut M. et al Entecavir treatment of chronic hepatitis D. Clin Infect Dis 2012; 55: 645-650
352 Soriano V, Vispo E, Sierra-Enguita R. et al Efficacy of prolonged tenofovir therapy on Hepatitis delta in HIV-infected patients. Aids 2014; 28: 2389-2394
353 Béguelin C, Friolet N, Moradpour D. et al Impact of tenofovir on hepatitis delta virus replication in the Swiss Human Immunodeficiency Virus Cohort Study. Clin Infect Dis 2017; 64: 1275-1278
354 Murata K, Asano M, Matsumoto A. et al Induction of IFN-λ 3 as an additional effect of nucleotide, not nucleoside, analogues: A new potential target for HBV infection. Gut 2018; 67: 362-371
355 Heidrich B, Deterding K, Tillmann HL. et al Virological and clinical characteristics of delta hepatitis in Central Europe. J Viral Hepat 2009; 16: 883-894
356 Sureau C, Negro F. The hepatitis delta virus: Replication and pathogenesis. J Hepatol 2016; 64: S102-S116
357 Amin J, Law MG, Bartlett M. et al Causes of death after diagnosis of hepatitis B or hepatitis C infection: a large community-based linkage study. Lancet 2006; 368: 938-945
358 Donato F, Boffetta P, Puoti M. A meta-analysis of epidemiological studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma. Int J Cancer 1998; 75: 347-354
359 Shi J, Zhu L, Liu S. et al A meta-analysis of case-control studies on the combined effect of hepatitis B and C virus infections in causing hepatocellular carcinoma in China. Br J Cancer 2005; 92: 607-612
360 Cho LY, Yang JJ, Ko KP. et al Coinfection of hepatitis B and C viruses and risk of hepatocellular carcinoma: Systematic review and meta-analysis. Int J Cancer 2011; 128: 176-184
361 Mak LY, Ka-Ho Wong D, Pollicino T. et al Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance. J Hepatol 2020; 73: 952-964
362 Wiegand SB, Jaroszewicz J, Potthoff A. et al Dominance of hepatitis C virus (HCV) is associated with lower quantitative hepatitis B surface antigen and higher serum interferon-γ-induced protein 10 levels in HBV/HCV-coinfected patients. Clin Microbiol Infect 2015; 21: 710.e1-710.e9
363 Sagnelli E, Sagnelli C, Macera M. et al An update on the treatment options for HBV/HCV coinfection. Expert Opin Pharmacother 2017; 18: 1691-1702
364 Liu CJ, Chuang WL, Sheen IS. et al Efficacy of Ledipasvir and Sofosbuvir Treatment of HCV Infection in Patients Coinfected With HBV. Gastroenterology 2018; 154: 989-997
365 Potthoff A, Berg T, Wedemeyer H. Late hepatitis B virus relapse in patients co-infected with hepatitis B virus and hepatitis C virus after antiviral treatment with pegylated interferon-a2b and ribavirin. Scand J Gastroenterol 2009; 44: 1487-1490
366 Chen G, Wang C, Chen J. et al Hepatitis B reactivation in hepatitis B and C coinfected patients treated with antiviral agents: A systematic review and meta-analysis. Hepatology 2017; 66: 13-26
367 Mücke MM, Backus LI, Mücke VT. et al Hepatitis B virus reactivation during direct-acting antiviral therapy for hepatitis C: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol 2018; 3: 172-180
368 Omland LH, Christensen PB, Krarup H. et al Mortality among patients with cleared hepatitis C virus infection compared to the general population: A danish nationwide cohort study. PLoS One 2011; 6: e22476
369 Sarrazin C, Isakov V, Svarovskaia ES. et al Late relapse versus hepatitis c virus reinfection in patients with sustained virologic response after sofosbuvir-based therapies. Clin Infect Dis 2017; 64: 44-52
370 Leumi S, Bigna JJ, Amougou MA. et al Global Burden of Hepatitis B Infection in People Living With Human Immunodeficiency Virus: A Systematic Review and Meta-analysis. Clin Infect Dis 2020; 71: 2799-2806
371 Deutsch-österreichische Leitlinien zur antiretroviralen Therapie der HIV-Infektion. 2003
372 European AIDS Clinical Society, (EACS). Treatment Guidelines 2016. 2016 Im Internet: http://www.eacsociety.org
373 Gallant J, Brunetta J, Crofoot G. et al Brief Report: Efficacy and Safety of Switching to a Single-Tablet Regimen of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide in HIV-1/Hepatitis B-Coinfected Adults. J Acquir Immune Defic Syndr 2016; 73: 294-298
374 Robert Koch-Institut. Zur Situation bei wichtigen Infektionskrankheiten in DeutschlandVirushepatitis B und D im Jahr 2014. Epidemiol Bull 2015; 29: 271-288
375 Gunardi H, Iskandar MY. et al Hepatitis B virus infection in children of HBV-related chronic liver disease patients: a study of intra-familial HBV transmission. Hepatol Int 2017; 11: 96-104
376 Chen JC, Chang ML, Lin JN. et al Comparison of childhood hepatic malignancies in a hepatitis B hyper-endemic area. World J Gastroenterol 2005; 11: 5289-5294
377 Ranger-Rogez S, Denis F. Hepatitis B mother-to-child transmission. Expert Rev Anti Infect Ther 2004; 2: 133-145
378 Tseng YR, Wu JF, Kong MS. et al Infantile hepatitis B in immunized children: Risk for fulminant hepatitis and long-term outcomes. PLoS One 2014; 9: e111825
379 Tabor E. Infections by hepatitis B surface antigen gene mutants in Europe and North America. J Med Virol 2006; 78 (Suppl. 01) S43-S47
380 Gigliotti AR, Fioredda F, Giacchino R. Hepatitis B and C infection in children undergoing chemotherapy or bone marrow transplantation. J Pediatr Hematol Oncol 2003; 25: 184-192
381 Lackner H, Moser A, Benesch M. et al Serological and molecular response on combined antiviral treatment in children with chronic hepatitis B after pediatric malignancy. Journal of Clinical Virology 2002; 25 (Suppl. 03) S73-S79
382 Thomas HC, Lok ASF, Locarnini SA. et al. (Hrsg) Viral Hepatitis. Wiley. Wiley-Blackwell; 2013
383 Kelly D. Viral hepatitis in children. Boston, MA: Springer; 2004
384 Bortolotti F, Guido M, Bartolacci S. et al Chronic hepatitis B in children after e antigen seroclearance: Final report of a 29-year longitudinal study. Hepatology 2006; 43: 556-562
385 Popalis C, Yeung LTF, Ling SC. et al Chronic hepatitis B virus (HBV) infection in children: 25 years’ experience. J Viral Hepat 2013; 20: e20-e26
386 Wintermeyer P, Gerner P, Gehring S. et al Prevalence of hepatitis B virus precore stop codon mutations in chronically infected children. World J Gastroenterol 2006; 12: 2235-2238
387 Chen CY, Ni YH, Chen HL. et al Lamivudine treatment in infantile fulminant hepatitis B. Pediatr Int 2010; 52: 672-674
388 Laubscher B, Gehri M, Roulet M. et al Survival of infantile fulminant hepatitis B and treatment with lamivudine. J Pediatr Gastroenterol Nutr 2005; 40: 518-520
389 Diamanti A, Sartorelli MR, Alterio A. et al Successful tenofovir treatment for fulminant hepatitis B infection in an infant. Pediatr Infect Dis J 2011; 30: 912-914
390 Hartman C, Berkowitz D, Eshach-Adiv O. et al Long-term lamivudine therapy for chronic hepatitis b infection in children unresponsive to interferon. J Pediatr Gastroenterol Nutr 2006; 43: 494-498
391 Jonas MM, Lok ASF, Mcmahon BJ. et al Antiviral therapy in management of chronic hepatitis B viral infection in children: A systematic review and meta-analysis. Hepatology 2016; 63: 307-318
392 Jonas MM, Chang MH, Sokal E. et al Randomized, controlled trial of entecavir versus placebo in children with hepatitis B envelope antigen-positive chronic hepatitis B. Hepatology 2016; 63: 377-387
393 Jonas MM, Kelley DA, Mizerski J. et al Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 2002; 346: 1706-1713
394 Diem HVT, Bourgois A, Bontems P. et al Chronic hepatitis B infection: Long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr 2005; 40: 141-145
395 Hom X, Little NR, Gardner SD. et al Predictors of Virologic Response to Lamivudine Treatment in Children with Chronic Hepatitis B Infection. Pediatr Infect Dis J 2004; 23: 441-445
396 Bortolotti F, Iorio R, Pace M. et al Long term effect of alpha interferon in children with chronic hepatitis B. Gut 2000; 46: 715-718
397 Wirth S, Zhang H, Hardikar W. et al Efficacy and Safety of Peginterferon Alfa-2a (40KD) in Children With Chronic Hepatitis B: The PEG-B-ACTIVE Study. Hepatology 2018; 68: 1681-1694
398 Sobaniec-Lotowska ME, Lebensztejn DM. Histological outcome of chronic hepatitis B in children treated with interferon alpha. World J Gastroenterol 2005; 11: 7179-7182
399 Saltik-Temizel IN, Koçak N, Demir H. Lamivudine and high-dose interferon-α combination therapy for naive children with chronic hepatitis B infection. J Clin Gastroenterol 2005; 39: 68-70
400 Defresne F, Sokal E. Chronic hepatitis B in children: Therapeutic challenges and perspectives. J Gastroenterol Hepatol 2017; 32: 368-371
401 Jonas MM, Kelly D, Pollack H. et al Efficacy and safety of long-term adefovir dipivoxil therapy in children with chronic hepatitis B infection. Pediatr Infect Dis J 2012; 31: 578-582
402 Jonas MM, Kelly D, Pollack H. et al Safety, efficacy, and pharmacokinetics of adefovir dipivoxil in children and adolescents (age 2 to <18 years) with chronic hepatitis B. Hepatology 2008; 47: 1863-1871
403 Murray KF, Szenborn L, Wysocki J. et al Randomized, placebo-controlled trial of tenofovir disoproxil fumarate in adolescents with chronic hepatitis B. Hepatology 2012; 56: 2018-2026
404 Carey I, D’Antiga L, Bansal S. et al Immune and Viral Profile from Tolerance to Hepatitis B Surface Antigen Clearance: a Longitudinal Study of Vertically Hepatitis B Virus-Infected Children on Combined Therapy. J Virol 2011; 85: 2416-2428
405 Poddar U, Yachha SK, Agarwal J. et al Cure for immune-tolerant hepatitis B in children: Is it an achievable target with sequential combo therapy with lamivudine and interferon?. J Viral Hepat 2013; 20: 311-316
406 Zhu S, Zhang H, Dong Y. et al Antiviral therapy in hepatitis B virus-infected children with immune-tolerant characteristics: A pilot open-label randomized study. J Hepatol 2018; 68: 1123-1128
407 Rosenthal P, Ling SC, Belle SH. et al Combination of Entecavir/Peginterferon Alfa-2a in Children With Hepatitis B e Antigen–Positive Immune Tolerant Chronic Hepatitis B Virus Infection. Hepatology 2019; 69: 2326-2337
408 Robert Koch-Institut. Impfstatus der Kinder und Jugendlichen in Deutschland, STIKO: Influenzaimpfungen in der COVID-19-Pandemie. Epidemiol Bull 2020; 32/33: 12
409 Lee C, Gong Y, Brok J. et al Effect of hepatitis B immunisation in newborn infants of mothers positive for hepatitis B surface antigen: Systematic review and meta-analysis. Br Med J 2006; 332: 328-332